GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoviricides Inc (AMEX:NNVC) » Definitions » Cyclically Adjusted PB Ratio

Nanoviricides (Nanoviricides) Cyclically Adjusted PB Ratio : 0.36 (As of May. 14, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Nanoviricides Cyclically Adjusted PB Ratio?

As of today (2024-05-14), Nanoviricides's current share price is $2.26. Nanoviricides's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $6.32. Nanoviricides's Cyclically Adjusted PB Ratio for today is 0.36.

The historical rank and industry rank for Nanoviricides's Cyclically Adjusted PB Ratio or its related term are showing as below:

NNVC' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.32
Current: 0.29

During the past years, Nanoviricides's highest Cyclically Adjusted PB Ratio was 0.32. The lowest was 0.00. And the median was 0.00.

NNVC's Cyclically Adjusted PB Ratio is ranked better than
79.84% of 645 companies
in the Biotechnology industry
Industry Median: 1.79 vs NNVC: 0.29

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Nanoviricides's adjusted book value per share data for the three months ended in Dec. 2023 was $1.057. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $6.32 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Nanoviricides Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Nanoviricides's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanoviricides Cyclically Adjusted PB Ratio Chart

Nanoviricides Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.72 1.12 0.69 0.28 0.18

Nanoviricides Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.18 0.18 0.21 0.16

Competitive Comparison of Nanoviricides's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Nanoviricides's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanoviricides's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanoviricides's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Nanoviricides's Cyclically Adjusted PB Ratio falls into.



Nanoviricides Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Nanoviricides's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.26/6.32
=0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanoviricides's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Nanoviricides's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.057/129.4194*129.4194
=1.057

Current CPI (Dec. 2023) = 129.4194.

Nanoviricides Quarterly Data

Book Value per Share CPI Adj_Book
201403 11.745 99.695 15.247
201406 8.556 100.560 11.012
201409 13.027 100.428 16.788
201412 10.786 99.070 14.090
201503 11.149 99.621 14.484
201506 11.104 100.684 14.273
201509 10.665 100.392 13.749
201512 9.816 99.792 12.730
201603 8.272 100.470 10.655
201606 7.922 101.688 10.082
201609 6.948 101.861 8.828
201612 6.549 101.863 8.321
201703 7.104 102.862 8.938
201706 6.419 103.349 8.038
201709 5.847 104.136 7.267
201712 5.022 104.011 6.249
201803 5.549 105.290 6.821
201806 5.106 106.317 6.216
201809 4.604 106.507 5.594
201812 3.982 105.998 4.862
201903 3.313 107.251 3.998
201906 2.757 108.070 3.302
201909 2.369 108.329 2.830
201912 1.995 108.420 2.381
202003 1.866 108.902 2.218
202006 2.395 108.767 2.850
202009 2.811 109.815 3.313
202012 2.599 109.897 3.061
202103 2.772 111.754 3.210
202106 2.598 114.631 2.933
202109 2.456 115.734 2.746
202112 2.294 117.630 2.524
202203 2.143 121.301 2.286
202206 1.991 125.017 2.061
202209 1.857 125.227 1.919
202212 1.708 125.222 1.765
202303 1.562 127.348 1.587
202306 1.271 128.729 1.278
202309 1.104 129.860 1.100
202312 1.057 129.419 1.057

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Nanoviricides  (AMEX:NNVC) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Nanoviricides Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Nanoviricides's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanoviricides (Nanoviricides) Business Description

Traded in Other Exchanges
Address
1 Controls Drive, Shelton, CT, USA, 06484
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
Executives
Makarand Jawadakar director C.O NANOVIRICIDES, INC, 1 CONTROLS DRIVE, SHELTON CT 06484
Mark D. Day director C/O NANOVIRICIDES, INC., 1 CONTROLS DRIVE, SHELTON CT 06484
Milton Boniuk director C/O NANOVIRICIDES, INC., 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Anil Diwan director, 10 percent owner, officer: President 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Mukund S Kulkarni director C/O NANOVIRICIDES, INC., 135 WOOD ST, SUITE 205, WEST HAVEN CT 06516
Meeta Vyas officer: Chief Financial Officer 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Eugene Seymour director, 10 percent owner 666 THIRD AVENUE, NEW YORK NY 10017
Theracour Pharma, Inc. 10 percent owner 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516

Nanoviricides (Nanoviricides) Headlines

From GuruFocus